Crisis in Ukraine may impact review times and the prioritisation of cases

07 March 2022

As a result of the crisis in Ukraine, the Danish Medicines Agency performs tasks relating to the supply of medicines to the Danish market.

The situation in Ukraine may influence our ability to meet our review times for applications for marketing authorisations, variations and renewals as well as applications for parallel import. The reason is that medicines that are going to be more needed during the current crisis will be dealt with first – especially applications deciding if a medicine can be marketed.

At the Danish Medicines Agency, we are doing all we can to review applications within the time limits agreed.

As always, pharmaceutical companies are welcome to write to godkendelse@dkma.dk if they have submitted an application and believe its review is decisive for the medicine to be marketed.

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.


...